Regeneron Pharmaceuticals reports Q4 earnings beat; initiates FY23 guidance
Regeneron Pharmaceuticals press release (NASDAQ:REGN): Q4 Non-GAAP EPS of $12.56  beats by $2.55.
Revenue of $3.41B (-31.1% Y/Y)  beats by $300M.
Fourth quarter 2022 EYLEAÂ® U.S. net sales decreased 3% to $1.50 billion versus fourth quarter 2021.
Fourth quarter 2022 DupixentÂ® global net sales (recorded by Sanofi) increased 38% to $2.45 billion versus fourth quarter 2021.

"In 2023, we remain committed to achieving the full potential of our diverse commercial- and clinical-stage portfolio, with a particular focus on aflibercept 8 mg, Dupixent in a variety of type 2 allergic diseases, and our promising oncology and hematology assets."

FY2023, the company now expects adjusted gross margin on net product sales of 90%â92%; Capital expenditures of $825Mâ$950M; Non-GAAP effective tax rate of 11%â13%.